Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cytomegalovirus (HHV-5) Infections-Pipeline Review, H2 2016

Cytomegalovirus (HHV-5) Infections-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Cytomegalovirus (HHV-5) Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections-Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cytomegalovirus (HHV-5) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections-Overview 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections-Comparative Analysis 11

Cytomegalovirus (HHV-5) Infections-Therapeutics under Development by Companies 12

Cytomegalovirus (HHV-5) Infections-Therapeutics under Investigation by Universities/Institutes 14

Cytomegalovirus (HHV-5) Infections-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Cytomegalovirus (HHV-5) Infections-Products under Development by Companies 20

Cytomegalovirus (HHV-5) Infections-Products under Investigation by Universities/Institutes 23

Cytomegalovirus (HHV-5) Infections-Companies Involved in Therapeutics Development 25

Adicet Bio, Inc. 25

AIMM Therapeutics BV 26

Astellas Pharma Inc 27

Atara Biotherapeutics Inc 28

AvidBiotics Corp 29

Biotest AG 30

Chimerix Inc 31

China Biologic Products Inc 32

CyTuVax BV 33

Fate Therapeutics Inc 34

GlaxoSmithKline Plc 35

Hookipa Biotech AG 36

Kadmon Corp LLC 37

Laboratoires Thea SA 38

Merck & Co Inc 39

Microbiotix Inc 40

Mymetics Corp 41

Novartis AG 42

Pfizer Inc 43

Phoenix Biotechnology Inc 44

Savoy Pharmaceuticals, Inc. 45

Sigma-Tau SpA 46

Themis Bioscience GmbH 47

Trellis Bioscience Inc 48

Vakzine Projekt Management GmbH 49

VBI Vaccines Inc 50

Vical Inc 51

Cytomegalovirus (HHV-5) Infections-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Combination Products 53

Assessment by Target 54

Assessment by Mechanism of Action 56

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

AIC-387-Drug Profile 62

AIC-476-Drug Profile 63

AIC-813-Drug Profile 64

AL-18-Drug Profile 65

Antibody for Human Cytomegalovirus Infection-Drug Profile 66

ASP-0113-Drug Profile 67

brincidofovir-Drug Profile 70

BT-084-Drug Profile 84

Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections-Drug Profile 85

Cellular Immunotherapy for Cytomegalovirus Infections-Drug Profile 86

Cellular Immunotherapy for Cytomegalovirus Infections-Drug Profile 87

Cellular Immunotherapy for Cytomegalovirus Infections-Drug Profile 88

Cellular Immunotherapy for Cytomegalovirus Infections-Drug Profile 89

Cellular Immunotherapy for Cytomegalovirus Infections and GBM-Drug Profile 90

Cellular Immunotherapy for Infectious Disease-Drug Profile 91

Cellular Immunotherapy for Infectious Diseases-Drug Profile 92

Cellular Immunotherapy for Viral Infections-Drug Profile 93

Cellular Immunotherapy for Viral Infections Post-HSCT-Drug Profile 94

Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections-Drug Profile 95

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections-Drug Profile 96

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections-Drug Profile 98

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 99

CMX-669-Drug Profile 100

CSJ-148-Drug Profile 101

CyMVectin-Drug Profile 102

cytomegalovirus (virus like particle) vaccine-Drug Profile 104

Cytomegalovirus (virus like particle) vaccine-Drug Profile 105

Cytomegalovirus vaccine-Drug Profile 106

Cytomegalovirus vaccine-Drug Profile 107

Cytomegalovirus vaccine-Drug Profile 108

filociclovir-Drug Profile 109

ganciclovir-Drug Profile 111

Gene Therapy for Cytomegalovirus Infections-Drug Profile 112

HB-101-Drug Profile 113

letermovir-Drug Profile 114

maribavir-Drug Profile 117

MBX-2168-Drug Profile 120

Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections-Drug Profile 121

Monoclonal Antibody for Cytomegalovirus Infections-Drug Profile 122

Monoclonal Antibody to Agonize LTbR for CMV Infection-Drug Profile 123

Pentamer-Drug Profile 124

Peptides to Inhibit Heparan Sulfate for HHV-5 Infections-Drug Profile 125

PepVax-Drug Profile 126

ProTmune-Drug Profile 128

PTX-3-Drug Profile 130

RBT-301-Drug Profile 131

Recombinant Peptide for Infectious Diseases-Drug Profile 132

Recombinant Protein for CMV-Drug Profile 133

RKP-00156-Drug Profile 134

Small Molecule for Cytomegalovirus-Drug Profile 135

Small Molecules for CMV Infections-Drug Profile 136

Small Molecules for CMV infections and Cancer-Drug Profile 137

Small Molecules to Activate Sirtuin for Viral Infections-Drug Profile 138

Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections-Drug Profile 139

Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases-Drug Profile 140

Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections-Drug Profile 141

Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease-Drug Profile 142

Triplex-Drug Profile 143

TRL-345-Drug Profile 145

V-160-Drug Profile 146

VBI-1501A-Drug Profile 147

Viralym-C-Drug Profile 149

Viroprev-Drug Profile 150

VPM-2001-Drug Profile 151

Cytomegalovirus (HHV-5) Infections-Dormant Projects 152

Cytomegalovirus (HHV-5) Infections-Discontinued Products 157

Cytomegalovirus (HHV-5) Infections-Product Development Milestones 158

Featured News & Press Releases 158

Appendix 172

Methodology 172

Coverage 172

Secondary Research 172

Primary Research 172

Expert Panel Validation 172

Contact Us 172

Disclaimer 173

List of Figures

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Top 10 Targets, H2 2016 58

Number of Products by Stage and Top 10 Targets, H2 2016 58

Number of Products by Top 10 Mechanism of Actions, H2 2016 60

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 60

Number of Products by Routes of Administration, H2 2016 62

Number of Products by Stage and Routes of Administration, H2 2016 62

Number of Products by Top 10 Molecule Types, H2 2016 64

Number of Products by Stage and Top 10 Molecule Types, H2 2016 64

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Comparative Analysis by Unknown Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 28

Cytomegalovirus (HHV-5) Infections-Pipeline by Adicet Bio, Inc., H2 2016 29

Cytomegalovirus (HHV-5) Infections-Pipeline by AIMM Therapeutics BV, H2 2016 30

Cytomegalovirus (HHV-5) Infections-Pipeline by Astellas Pharma Inc, H2 2016 31

Cytomegalovirus (HHV-5) Infections-Pipeline by Atara Biotherapeutics Inc, H2 2016 32

Cytomegalovirus (HHV-5) Infections-Pipeline by AvidBiotics Corp, H2 2016 33

Cytomegalovirus (HHV-5) Infections-Pipeline by Biotest AG, H2 2016 34

Cytomegalovirus (HHV-5) Infections-Pipeline by Chimerix Inc, H2 2016 35

Cytomegalovirus (HHV-5) Infections-Pipeline by China Biologic Products Inc, H2 2016 36

Cytomegalovirus (HHV-5) Infections-Pipeline by CyTuVax BV, H2 2016 37

Cytomegalovirus (HHV-5) Infections-Pipeline by Fate Therapeutics Inc, H2 2016 38

Cytomegalovirus (HHV-5) Infections-Pipeline by GlaxoSmithKline Plc, H2 2016 39

Cytomegalovirus (HHV-5) Infections-Pipeline by Hookipa Biotech AG, H2 2016 40

Cytomegalovirus (HHV-5) Infections-Pipeline by Kadmon Corp LLC, H2 2016 41

Cytomegalovirus (HHV-5) Infections-Pipeline by Laboratoires Thea SA, H2 2016 42

Cytomegalovirus (HHV-5) Infections-Pipeline by Merck & Co Inc, H2 2016 43

Cytomegalovirus (HHV-5) Infections-Pipeline by Microbiotix Inc, H2 2016 44

Cytomegalovirus (HHV-5) Infections-Pipeline by Mymetics Corp, H2 2016 45

Cytomegalovirus (HHV-5) Infections-Pipeline by Novartis AG, H2 2016 46

Cytomegalovirus (HHV-5) Infections-Pipeline by Pfizer Inc, H2 2016 47

Cytomegalovirus (HHV-5) Infections-Pipeline by Phoenix Biotechnology Inc, H2 2016 48

Cytomegalovirus (HHV-5) Infections-Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 49

Cytomegalovirus (HHV-5) Infections-Pipeline by Sigma-Tau SpA, H2 2016 50

Cytomegalovirus (HHV-5) Infections-Pipeline by Themis Bioscience GmbH, H2 2016 51

Cytomegalovirus (HHV-5) Infections-Pipeline by Trellis Bioscience Inc, H2 2016 52

Cytomegalovirus (HHV-5) Infections-Pipeline by Vakzine Projekt Management GmbH, H2 2016 53

Cytomegalovirus (HHV-5) Infections-Pipeline by VBI Vaccines Inc, H2 2016 54

Cytomegalovirus (HHV-5) Infections-Pipeline by Vical Inc, H2 2016 55

Assessment by Monotherapy Products, H2 2016 56

Assessment by Combination Products, H2 2016 57

Number of Products by Stage and Target, H2 2016 59

Number of Products by Stage and Mechanism of Action, H2 2016 61

Number of Products by Stage and Route of Administration, H2 2016 63

Number of Products by Stage and Molecule Type, H2 2016 65

Cytomegalovirus (HHV-5) Infections-Dormant Projects, H2 2016 156

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..1), H2 2016 157

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..2), H2 2016 158

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..3), H2 2016 159

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..4), H2 2016 160

Cytomegalovirus (HHV-5) Infections-Discontinued Products, H2 2016 161

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adicet Bio, Inc. , AIMM Therapeutics BV, Astellas Pharma Inc, Atara Biotherapeutics Inc, AvidBiotics Corp, Biotest AG , Chimerix Inc , China Biologic Products Inc, CyTuVax BV , Fate Therapeutics Inc, GlaxoSmithKline Plc, Hookipa Biotech AG, Kadmon Corp LLC, Laboratoires Thea SA, Merck & Co Inc , Microbiotix Inc , Mymetics Corp , Novartis AG , Pfizer Inc , Phoenix Biotechnology Inc, Savoy Pharmaceuticals, Inc., Sigma-Tau SpA , Themis Bioscience GmbH, Trellis Bioscience Inc, Vakzine Projekt Management GmbH, VBI Vaccines Inc, Vical Inc

Cytomegalovirus (HHV-5) Infections Therapeutic Products under Development, Key Players in Cytomegalovirus (HHV-5) Infections Therapeutics, Cytomegalovirus (HHV-5) Infections Pipeline Overview, Cytomegalovirus (HHV-5) Infections Pipeline, Cytomegalovirus (HHV-5) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com